Krishnaswamy Yeleswaram Sells 10,200 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Posted by George Bondi on Apr 14th, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) insider Krishnaswamy Yeleswaram sold 10,200 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $35.08, for a total transaction of $357,816.00. Following the completion of the transaction, the insider directly owned 266,651 shares of the company’s stock, valued at approximately $9,354,117.08. This trade represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Krishnaswamy Yeleswaram also recently made the following trade(s):

On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.97, for a total transaction of $320,500.05.
On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $34.98, for a total transaction of $17,490.00.
On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.90, for a total transaction of $12,564.00.

Rapport Therapeutics Trading Up 4.3%

Shares of RAPP stock traded up $1.50 during trading hours on Tuesday, reaching $36.15. The stock had a trading volume of 496,199 shares, compared to its average volume of 328,964. The stock’s fifty day simple moving average is $29.41 and its 200 day simple moving average is $28.29. Rapport Therapeutics, Inc. has a 12 month low of $7.73 and a 12 month high of $42.27. The firm has a market capitalization of $1.73 billion, a PE ratio of -12.64 and a beta of 1.09.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). As a group, equities research analysts anticipate that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RAPP shares. Wells Fargo & Company lifted their target price on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a research report on Wednesday, March 11th. Truist Financial upgraded shares of Rapport Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. Citigroup reiterated a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, March 10th. Finally, BTIG Research lifted their target price on shares of Rapport Therapeutics to $47.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $53.83.

View Our Latest Stock Analysis on Rapport Therapeutics

Institutional Investors Weigh In On Rapport Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Strs Ohio lifted its position in Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after purchasing an additional 400 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Rapport Therapeutics by 56.9% during the fourth quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company’s stock valued at $69,000 after purchasing an additional 828 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Rapport Therapeutics by 64.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock valued at $70,000 after purchasing an additional 905 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Rapport Therapeutics in the 4th quarter worth approximately $37,000. Finally, Creative Planning lifted its holdings in shares of Rapport Therapeutics by 12.8% in the 3rd quarter. Creative Planning now owns 11,959 shares of the company’s stock worth $355,000 after acquiring an additional 1,357 shares during the last quarter.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.